Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study

BackgroundEffective adjuvant therapy for osteosarcoma is necessary for improved outcomes. Previous studies demonstrated that apatinib plus doxorubicin-based chemotherapy may improve the efficacy of neoadjuvant therapy. This study aimed to clarify the effectiveness and safety of apatinib plus doxorub...

Full description

Bibliographic Details
Main Authors: Jiaqiang Wang, Fan Zhang, Shuping Dong, Yang Yang, Fangfang Gao, Guancong Liu, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Oncology
Subjects:
apatinib
doxorubicin
cisplatin
osteosarcoma
neoadjuvant therapy
adverse events
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1227461/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1227461/full

Similar Items